UniSuper Management Pty Ltd Has $58.21 Million Holdings in AbbVie Inc. $ABBV

UniSuper Management Pty Ltd increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 9.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 251,394 shares of the company’s stock after acquiring an additional 21,547 shares during the quarter. UniSuper Management Pty Ltd’s holdings in AbbVie were worth $58,208,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Conning Inc. raised its stake in shares of AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares during the last quarter. Diversified Trust Co increased its holdings in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after buying an additional 10,891 shares in the last quarter. Dohj LLC raised its position in AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after buying an additional 1,335 shares during the last quarter. Permanent Capital Management LP bought a new position in AbbVie during the 3rd quarter valued at about $720,000. Finally, Railway Pension Investments Ltd boosted its holdings in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of ABBV stock opened at $219.21 on Friday. The company has a market cap of $387.42 billion, a price-to-earnings ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a fifty day moving average price of $225.60 and a 200-day moving average price of $217.22.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the previous year, the business earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is presently 524.24%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ABBV shares. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, JPMorgan Chase & Co. increased their target price on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $248.11.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.